Healthcare Industry News: Roche
News Release - May 2, 2011
HTG Molecular Diagnostics Appoints John Lubniewski to Chief Business OfficerTUCSON, Ariz.--(Healthcare Sales & Marketing Network)-- HTG Molecular Diagnostics, provider of molecular technology solutions, today announced the appointment of John Lubniewski to Chief Business Officer.
Mr. Lubniewski brings more than 20 years of management experience in the life science sector to this newly created position at HTG. He will be responsible for leading the sales, marketing and product development teams for HTG’s three strategic business areas: molecular testing capabilities for translational medicine, pharmaceutical clinical development and pathology laboratory diagnostics.
“John has extensive experience in strategic marketing, product development and business unit management and he is adeptly suited to both strengthen our existing sales and marketing efforts for existing products as well as help to drive development of new technologies and offerings for HTG Molecular Diagnostics,” said TJ Johnson, CEO of HTG Molecular Diagnostics. “His skills, combined with his in-depth knowledge of the research tools, companion diagnostics and pathology markets, make him an outstanding addition to our seasoned management team.”
Prior to joining HTG, Mr. Lubniewski held multiple senior management positions at Ventana Medical Systems, a member of the Roche Group and innovator of tissue-based diagnostic solutions. His roles at Ventana included Lifecycle Leader of Advanced Staining Platforms and Senior Vice President of Clinical Assays. Mr. Lubniewski has also served as Director of New Business Development and Business Unit Manager at Corning, Inc. He began his career in the Industrial Chemicals Division of Procter & Gamble.
Mr. Lubniewski received his B.S. in Chemical Engineering from Clarkson University.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics is a leading provider of molecular-based technology solutions for gene expression profiling, miRNA, siRNA and mRNA measurement for translational medicine and diagnostic applications. The Company’s qNPA™ molecular technology platform is well-suited for reliably detecting small, yet important, changes in gene expression levels in a variety of sample types. Privately-held HTG is based in Tucson, Arizona. Additional information is available at www.htgmolecular.com.
Source: HTG Molecular Diagnostics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.